Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.

ConditionPityriasis Versicolor

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18-50

SponsorPAEC General Hospital, Islamabad

About this trial

Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All patients diagnosed with pityriasis versicolor.

Disqualifiers

Immunocompromised patients

Trial design

Design model

Parallel

Treatments tested in this trial

Luliconazole Cream 1%
Drug
Ketoconazole is relatively hydrophilic with limited skin retention, whereas luliconazole is highly lipophilic, resulting in superior stratum corneum penetration, higher keratin binding, and prolonged antifungal activity.
Topical ketoconazole 2% cream
Drug
Ketoconazole is relatively hydrophilic with limited skin retention, whereas luliconazole is highly lipophilic, resulting in superior stratum corneum penetration, higher keratin binding, and prolonged antifungal activity.

Treatment groups

86 Participants

are divided into 2 treatment groups

Group A: Topical Luliconazole 1% creamExperimental treatment 1 intervention

Group B: Topical ketoconazole 2% creamExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Clinical and mycological cure rate in pityriasis versicolor.

Proportion of participants achieving both clinical and mycological cure.

Time frame

4 weeks

Clinical and mycological cure

Proportion of participants achieving both clinical and mycological cure

Time frame

4 weeks after completion of treatment

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

PAEC General Hospital, Islamabad

Lead sponsor

PAEC general hospital

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: